 |
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Jul 12, 2011
|
19.9 KB |
|
| |
PARIS and TARRYTOWN, N.Y., July 12, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab (REGN88/SAR153191), a novel, high-affinity, subcutaneously administered, fully-human...
|
|
Phase 3 Trial of ZALTRAP™ (aflibercept) in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Jul 7, 2011
|
16.0 KB |
|
| |
TARRYTOWN, N.Y., July 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 VENICE clinical trial evaluating the investigational agent ZALTRAP™ (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to compl...
|
|
EYLEA™ (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
Jun 28, 2011
|
17.7 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, June 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA™, also known as VEGF Trap-Eye, for...
|
|
Regeneron Pharmaceuticals, Inc. Announces R-Unit Program to Help Educate, Sensitize and Energize Biotech Employees in Support of American Troops
Jun 27, 2011
|
11.5 KB |
|
| |
TARRYTOWN, N.Y., June 27, 2011 -- Regeneron Pharmaceuticals, Inc. today announced the launch of a program to support a U.S. Army Civil Affairs Unit - called R-Unit - that deployed to Iraq on June 7, 2011. The official kick-off event for the program took place at Regeneron's Corporate Headquarters in Tarrytown, New York on Friday, May 20, 2011, w...
|
|
Regeneron Announces EYLEA™ (aflibercept ophthalmic solution) Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee
Jun 17, 2011
|
13.2 KB |
|
| |
TARRYTOWN, N.Y., June 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted unanimously to recommend that the FDA approve EYLEA™, also known as VEGF Trap-Eye, for the treatment of the neovasc...
|
|
Trading in Regeneron Common Stock Halted
Jun 17, 2011
|
11.8 KB |
|
| |
TARRYTOWN, N.Y., June 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that NASDAQ has halted trading of the company's common stock today. The Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is meeting today to discuss the company's Biologics License Application (...
|
|
Regeneron President and CEO Leonard S. Schleifer Named Ernst & Young Entrepreneur Of The Year® 2011 New York Award Winner
Jun 13, 2011
|
10.6 KB |
|
| |
Tarrytown, New York, June 13, 2011 - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its president and chief executive officer, Leonard S. Schleifer, M.D., Ph.D., received the Ernst & Young Entrepreneur Of The Year® 2011 New York Award in the healthcare services category. The award recognizes outstand...
|
|
VEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular Degeneration
Jun 7, 2011
|
17.1 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, June 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and...
|
|
ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Jun 6, 2011
|
18.8 KB |
|
| |
PARIS and TARRYTOWN, N.Y., June 6, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data showing that the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, significantly improved survival in previously treated metastatic colorectal cancer pat...
|
|
FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
May 23, 2011
|
12.4 KB |
|
| |
TARRYTOWN, N.Y. May 23, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that it has scheduled a Dermatologic and Ophthalmic Drugs Advisory Committee Meeting to be held on June 17, 2011 to discuss the Company's Biologics License Application ...
|
|
Regeneron Reports First Quarter 2011 Financial and Operating Results
May 3, 2011
|
26.7 KB |
|
| |
TARRYTOWN, N.Y., May 3, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2011 and provided an update on development programs and upcoming milestones.
Clinical Programs Update
VEGF Trap-Eye (aflibercept ophthalmic solution) — Ophthalmologic Diseases
VEGF T...
|
|
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
May 2, 2011
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., May 2, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2011 Health Care Conference on Tuesday, May 10, 2011 at 9:20 a.m. Pacific Time (12:20 p.m. Eastern Time). The session may be accessed through the Company's web site, www.regeneron.com, on th...
|
|
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Apr 27, 2011
|
18.7 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, April 27, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). The positive results f...
|
|
Sanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAP™ (aflibercept) in Second-line Metastatic Colorectal Cancer
Apr 26, 2011
|
18.8 KB |
|
| |
PARIS and TARRYTOWN, N.Y., April 26, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen [fo...
|
|
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Apr 18, 2011
|
12.3 KB |
|
| |
TARRYTOWN, N.Y., April 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). The FDA ...
|
|
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Apr 8, 2011
|
18.0 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, April 8, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent for the treatment of certa...
|
|
Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
Mar 30, 2011
|
9.1 KB |
|
| |
TARRYTOWN, N.Y., March 30, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 10th Annual Needham Healthcare Conference on Wednesday, April 6, 2011 at 1:20 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archi...
|
|
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Mar 10, 2011
|
20.8 KB |
|
| |
PARIS and TARRYTOWN, N.Y., March 10, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC). The data s...
|
|
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Feb 28, 2011
|
23.2 KB |
|
| |
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 1...
|
|
Regeneron Announces March 2011 Investor Conference Presentations
Feb 23, 2011
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., Feb. 23, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
Citi 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on Tuesday, March 1, 2011RBC Capital Markets' 2011 Healthcare Conference at 10:00 a.m. Eastern Time on Wednesda...
|
|
|
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds